Earnings summaries and quarterly performance for American Well.
Executive leadership at American Well.
Board of directors at American Well.
Research analysts who have asked questions during American Well earnings calls.
Jailendra Singh
Truist Securities
6 questions for AMWL
Also covers: ACCD, AGL, ASTH +16 more
CH
Craig Hettenbach
Morgan Stanley
5 questions for AMWL
Also covers: ACCD, ARDT, DH +10 more
David Larsen
BTIG
5 questions for AMWL
Also covers: ACCD, AGL, ASTH +20 more
Eric Percher
Nephron Research
5 questions for AMWL
Also covers: CAH, COR, CVS +5 more
CR
Charles Rhyee
TD Cowen
3 questions for AMWL
Also covers: BTSG, CAH, CI +20 more
SB
Stanislav Berenshteyn
Wells Fargo
3 questions for AMWL
Also covers: DOCS, GDRX, HCAT +3 more
Jessica Tassan
Piper Sandler
2 questions for AMWL
Also covers: ACCD, ALHC, CMAX +12 more
Kevin Caliendo
UBS
2 questions for AMWL
Also covers: ACH, AHCO, ALGN +18 more
Matthew Shea
Needham & Company
2 questions for AMWL
Also covers: AGL, CHGG, DCBO +5 more
Ryan MacDonald
Needham & Company
2 questions for AMWL
Also covers: ACCD, BNED, CHGG +21 more
Dolph Warburton
Nephron Research
1 question for AMWL
JS
Jack Senft
William Blair
1 question for AMWL
Also covers: HCSG, LFST, MD +3 more
JW
Jack Wallace
Guggenheim Partners
1 question for AMWL
Also covers: ACCD, PHR, VEEV +1 more
JP
John Park
Morgan Stanley
1 question for AMWL
Also covers: BJ, CERT, DOCS
LR
Lucas Romanski
BTIG
1 question for AMWL
Also covers: DRIO, ICLR, OWLT
RM
Ryan McDonald
Needham
1 question for AMWL
Also covers: HNGE, MH, ODD +2 more
SB
Stan Berenshteyn
Wells Fargo Securities
1 question for AMWL
Also covers: DOCS, GDRX, HNGE +4 more
SB
Stan Berenstein
Wells Fargo
1 question for AMWL
Also covers: HQY
Recent press releases and 8-K filings for AMWL.
Amwell Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
AMWL
Earnings
Guidance Update
M&A
- Amwell reported total revenue of $55.3 million for Q4 2025, representing a 22.1% year-over-year decline, and $249.3 million for the full year 2025.
- For the full year 2025, the company significantly reduced both net loss and adjusted EBITDA losses by approximately $100 million each.
- In Q4 2025, Adjusted EBITDA loss improved to $10.3 million from $22.8 million in Q4 2024, and net loss was $25.2 million, a 43.5% year-over-year improvement.
- Amwell provided full-year 2026 revenue guidance in the range of $195 million to $205 million and Adjusted EBITDA loss guidance between $24 million and $18 million.
- The company expects to achieve positive cash flow from operations in the fourth quarter of 2026, driven by a strategic focus on its tech platform, divestiture of non-core activities like APC, and significant cost reductions.
Feb 12, 2026, 10:00 PM
Amwell Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
AMWL
Earnings
Guidance Update
- Amwell reported full-year 2025 total revenue of $249.3 million, with subscription revenue growing to 53% of total revenue from 45% in 2024, and reduced net loss and Adjusted EBITDA losses by approximately $100 million each. For Q4 2025, total revenue was $55.3 million, and Adjusted EBITDA loss improved to $10.3 million. The company ended 2025 with $182 million in cash and marketable securities and no debt.
- For full-year 2026, Amwell expects revenue between $195 million and $205 million and an Adjusted EBITDA loss between $18 million and $24 million. The company anticipates achieving positive cash flow from operations in Q4 2026.
- Amwell completed a major transformation in 2025, focusing exclusively on its technology-enabled care platform for payers and government, divesting non-core assets, and securing over 15 payer contract renewals, including a 3-year renewal with Elevance.
- The company is leveraging AI integration to enhance its platform, positioning itself as a crucial infrastructure for customers to adopt AI-powered clinical programs safely and effectively.
Feb 12, 2026, 10:00 PM
Amwell Reports Q4 2025 Results and Provides 2026 Guidance
AMWL
Earnings
Guidance Update
- Amwell reported FY 2025 total revenue of $249.3 million and Q4 2025 total revenue of $55.3 million, with subscription revenue comprising 53% of total revenue for the full year.
- The company provided FY 2026 revenue guidance of $195 million-$205 million and expects to achieve positive cash flow from operations in Q4 2026.
- In 2025, Amwell executed a major transformation, sharpening its focus exclusively on offering a tech platform and divesting non-core activities, aiming for higher quality, more predictable, SaaS-based revenue streams.
- This strategic shift led to a reduction in both net loss and adjusted EBITDA losses by approximately $100 million each for FY 2025, driven by disciplined cost actions.
Feb 12, 2026, 10:00 PM
Amwell Announces Fourth Quarter and Full Year 2025 Results and 2026 Guidance
AMWL
Earnings
Guidance Update
Demand Weakening
- Amwell reported total revenue of $55.3 million for the fourth quarter of 2025 and $249.3 million for the full year 2025.
- The company's net loss was ($25.2) million in Q4 2025 and ($95.0) million for the full year 2025, which is an improvement compared to ($212.6) million in 2024.
- Adjusted EBITDA for Q4 2025 was ($10.3) million, and for the full year 2025, it was ($39.9) million, significantly better than ($134.4) million in 2024.
- As of December 31, 2025, cash and short-term securities were approximately $182.3 million.
- For 2026, Amwell provides financial guidance expecting revenue in the range of $195 to $205 million and Adjusted EBITDA between ($24) million to ($18) million, with an objective to achieve positive cash flow from operations in the fourth quarter of 2026.
Feb 12, 2026, 9:11 PM
American Well Corporation Extends Key Agreements with Elevance Health
AMWL
New Projects/Investments
- American Well Corporation (AMWL) and its clinical partner, Online Care Group, PC, extended their Master Services Agreement and related provider agreements with Elevance Health, Inc. (formerly Anthem Inc.) for an additional three years, effective January 1, 2026, through January 1, 2029.
- Under these extended agreements, AMWL will continue to operate a white-labelled digital care delivery platform (LiveHealth Online®) for Elevance Health, receiving annual subscription fees and potential fees for professional services on a time and materials basis.
- The amendments also include updates to the contract term, Medicaid Exhibits, Required Information Security Controls (RISC) Exhibit, and add a provision pertaining to Artificial Intelligence (AI).
- Online Care Group, PC will continue to provide clinical professionals for digital care consultations to Elevance Health members and will receive a one-time provider access fee from Anthem by December 15, 2026.
Jan 2, 2026, 10:18 PM
AmWell Reports Q3 2025 Results, Updates Full-Year Guidance, and Reaffirms 2026 Cash Flow Break-Even Goal
AMWL
Earnings
Guidance Update
Layoffs
- AmWell reported Q3 2025 total revenue of $56.3 million, an 8% decrease year over year, though normalizing for the sale of APC, revenue would have increased by 1.3%. Subscription revenue grew 18% year over year to $30.9 million, comprising 55% of total revenue.
- The company significantly improved its profitability, reporting an Adjusted EBITDA loss of $12.7 million for Q3 2025, compared favorably to a loss of $31 million a year ago, primarily due to a 16% decrease in operating expenses and cost containment initiatives.
- AmWell updated its full-year 2025 revenue guidance to between $245 million and $248 million and narrowed its Adjusted EBITDA guidance to a loss between $45 million and $42 million. The company maintains its goal of achieving cash flow break-even from operations during 2026.
- The company ended Q3 2025 with approximately $201 million in cash and marketable securities and zero debt, with a cash burn of approximately $18 million for the quarter. Strategic efforts include focusing on its new platform, integrating AI, and pursuing further divestiture of non-core assets.
Nov 4, 2025, 10:00 PM
American Well Corporation Announces Q3 2025 Financial Results and Updates Guidance
AMWL
Earnings
Guidance Update
- American Well Corporation reported Total Revenue of $56.3 million for the third quarter ended September 30, 2025, with a net loss of ($31.9) million and Adjusted EBITDA of ($12.7) million.
- The company updated its 2025 revenue guidance to a range of $245 million to $248 million and narrowed its Adjusted EBITDA guidance to between ($45) million to ($42) million.
- For the fourth quarter of 2025, Amwell expects revenue in the range of $51 million to $54 million and Adjusted EBITDA in the range of ($15) million to ($12) million.
- Amwell also reiterated its objective to achieve positive cash flow from operations in 2026.
Nov 4, 2025, 9:13 PM
Quarterly earnings call transcripts for American Well.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more